This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.本發明係關於新穎2,3-二氫咪唑并[1,2-c]喹唑啉化合物、含有此等化合物之醫藥組合物及彼等化合物或組合物之用途,其作為唯一藥劑或與其他活性成份組合,用於抑制磷脂醯肌醇-3-激酶(PI3K)及治療與磷脂醯肌醇-3-激酶(PI3K)活性相關之疾病,特定言之治療過度增殖性及/或血管生成病症。無
